文献速递创伤骨科骨质疏松与代谢性骨病

1990年至2019年髋部骨折的流行病学与全球疾病负担:来自2019年全球疾病负担研究的分析与补充分析

What was the Epidemiology and Global Burden of Disease of Hip Fractures From 1990 to 2019? Results From and Additional Analysis of the Global Burden of Disease Study 2019.
PubMed 文献 · Clin Orthop Relat Res · 2022-11-02

本研究基于2019年全球疾病负担研究数据,分析1990至2019年204个国家的髋部骨折发病率与伤残损失寿命年。男性年龄标化发病率略有上升,女性发病率与伤残损失寿命年均高于男性。

要点

  • 跌倒为髋部骨折首要原因,占全部患者的66%和总伤残损失寿命年的55%。
  • 男性年龄标化发病率略有上升(EAPC 0.11,95%CI 0.01至0.2),全球两性合计发病率无变化。

核心结论

  • 髋部骨折常见、对患者具破坏性且给全球医疗系统带来经济负担,跌倒是首要原因。
  • 男性年龄标化发病率略有上升。
  • 许多低纬度国家发病率较低,可能因日照时间较长。
  • 作者建议政策应致力于促进关于保持骨保护性生活方式的公共卫生教育、增强年轻住院医师和执业医师对骨质疏松管理的知识、提高男性对骨质疏松筛查和治疗的意识、开发更有效的抗骨质疏松药物供临床使用。

研究设计与样本

  • 横断面研究,数据来自2019年全球疾病负担研究(GBD 2019),该研究由世界卫生组织管理、健康测量与评估研究所协调、比尔及梅琳达·盖茨基金会资助。
  • GBD 2019按年龄、性别和社会人口因素估计204个国家的疾病与伤害负担,所有估计值及95%不确定性区间(UI)采用贝叶斯meta回归工具DisMod-MR 2.1生成。
  • 本研究直接从GBD 2019提取按地点、年龄、性别和原因分层的髋部骨折年龄标化发病率和伤残损失寿命年率,分析发病率与各国纬度的关联,计算估计的年百分比变化以表示1990至2019年趋势,并用Spearman秩相关分析发病率或负担与社会人口指数的相关性。

主要发现

  • 发病率与各国纬度呈强正相关(rho=0.65;p<0.001)。
  • 1990至2019年,全球两性发病率保持不变(估计年百分比变化0.01[95%CI -0.08至0.11]),但男性略有上升(估计年百分比变化0.11[95%CI 0.01至0.2]);伤残损失寿命年率略有下降(估计年百分比变化0.66[95%CI -0.73至-0.6]),以上率均经年龄标化。
  • 跌倒为髋部骨折首要原因,占全部患者的66%和总伤残损失寿命年的55%;发病率与社会人口指数紧密正相关(rho 0.624;p<0.001),而伤残损失寿命年率呈轻度负相关(rho -0.247;p<0.001)。
  • 大多数髋部骨折发生于70岁以上人群,女性发病率(每10万人189.7[95%UI 144.2至247.2] vs 男性166.2[95%UI 133.2至205.8])和伤残损失寿命年(每10万人38.4[95%UI 26.9至51.6] vs 男性33.7[95%UI 23.1至45.5])均高于男性。

临床怎么用

  • 作者建议政策应致力于促进关于保持骨保护性生活方式的公共卫生教育。
  • 作者建议增强年轻住院医师和执业医师对骨质疏松管理的知识。
  • 作者建议提高男性对骨质疏松筛查和治疗的意识。
  • 作者建议开发更有效的抗骨质疏松药物供临床使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hip fractures are associated with a high risk of death; among those who survive a hip fracture, many experience substantial decreases in quality of life. A comprehensive understanding of the epidemiology and burden of hip fractures by country, age, gender, and sociodemographic factors would provide valuable information for healthcare policymaking and clinical practice. The Global Burden of Disease (GBD) study 2019 was a global-level study estimating the burden of 369 diseases and injuries in 204 countries and territories. An exploration and additional analysis of the GBD 2019 would provide a clearer picture of the incidence and burden of hip fractures. QUESTIONS/PURPOSES: Using data from the GBD 2019, we asked, (1) What are the global, regional, and national incidences of hip fractures, and how did they change over a recent 30-year span? (2) What is the global, regional, and national burden of hip fractures in terms of years lived with disability, and how did it change over that same period? (3) What is the leading cause of hip fractures? (4) How did the incidence and years lived with disability of patients with hip fractures change with age, gender, and sociodemographic factors? METHODS: This was a cross-sectional study. Participant data were obtained from the GBD 2019 ( http://ghdx.healthdata.org/gbd-results-tool ). The GBD study is managed by the WHO, coordinated by the Institute of Health Metrics and Evaluation, and funded by the Bill and Melinda Gates Foundation. It estimates the burden of disease and injury for 204 countries by age, gender, and sociodemographic factors, and can serve as a valuable reference for health policymaking. All estimates and their 95% uncertainty interval (UI) were produced using DisMod-MR 2.1, a Bayesian meta-regression tool in the GBD 2019. In this study, we directly pulled the age-standardized incidence rate and years lived with disability rate of hip fractures by location, age, gender, and cause from the GBD 2019. Based on these data, we analyzed the association between the incidence rate and latitude of each country. Then, we calculated the estimated annual percentage change to represent trends from 1990 to 2019. We also used the Spearman rank-order correlation analysis to determine the correlation between the incidence or burden of hip fractures and the sociodemographic index, a composite index of the income per capita, average years of educational attainment, and fertility rates in a country. RESULTS: Globally, hip fracture incidences were estimated to be 14.2 million (95% UI 11.1 to 18.1), and the associated years lived with disability were 2.9 million (95% UI 2.0 to 4.0) in 2019, with an incidence of 182 (95% UI 142 to 231) and 37 (95% UI 25 to 50) per 100,000, respectively. A strong, positive correlation was observed between the incidence rate and the latitude of each country (rho = 0.65; p < 0.001). From 1990 to 2019, the global incidence rate for both genders remained unchanged (estimated annual percentage change 0.01 [95% confidence interval -0.08 to 0.11]), but was slightly increased in men (estimated annual percentage change 0.11 [95% CI 0.01 to 0.2]). The years lived with disability rate decreased slightly (estimated annual percentage change 0.66 [95% CI -0.73 to -0.6]). These rates were standardized by age. Falls were the leading cause of hip fractures, accounting for 66% of all patients and 55% of the total years lived with disability. The incidence of hip fractures was tightly and positively correlated with the sociodemographic index (rho 0.624; p < 0.001), while the years lived with disability rate was slightly negatively correlated (rho -0.247; p < 0.001). Most hip fractures occurred in people older than 70 years, and women had higher incidence rate (189.7 [95% UI 144.2 to 247.2] versus 166.2 [95% UI 133.2 to 205.8] per 100,000) and years lived with disability (38.4 [95% UI 26.9 to 51.6] versus 33.7 [95% UI 23.1 to 45.5] per 100,000) than men. CONCLUSION: Hip fractures are common, devastating to patients, and economically burdensome to healthcare systems globally, with falls being the leading cause. The age-standardized incidence rate has slightly increased in men. Many low-latitude countries have lower incidences, possibly because of prolonged sunlight exposure. Policies should be directed to promoting public health education about maintaining bone-protective lifestyles, enhancing the knowledge of osteoporosis management in young resident physicians and those in practice, increasing the awareness of osteoporosis screening and treatment in men, and developing more effective antiosteoporosis drugs for clinical use. LEVEL OF EVIDENCE: Level III, prognostic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Dong Y, Zhang Y, Song K, et al. What was the Epidemiology and Global Burden of Disease of Hip Fractures From 1990 to 2019? Results From and Additional Analysis of the Global Burden of Disease Study 2019. Clin Orthop Relat Res. 2022. PMID: 36374576. doi:10.1097/CORR.0000000000002465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。